Chlamydia infection
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Chlamydia Classification and external resources | |
 | |
|---|---|
| Pap smear showing C. trachomatis (H&E stain) | |
| ICD-10 | A55.-A56.8, A70.-A74.9 |
| ICD-9 | 099.41, 483.1 |
| DiseasesDB | 2384 |
| eMedicine | med/340 |
| MeSH | D002690 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
- The term Chlamydia refers to an infection by any one of the species in the bacterial genus Chlamydia—Chlamydia trachomatis, Chlamydia suis or Chlamydia muridarum—, but of these, only C. trachomatis is found in humans.[1] For a list of species formerly included in the genus Chlamydia, please see Chlamydophila.[1]
Chlamydia (from the Greek, χλαμύδος meaning "cloak") is a common sexually transmitted disease (STD) caused by the bacterium, Chlamydia trachomatis. Chlamydia is a major infectious cause of human eye and genital disease.
C. trachomatis is naturally found living only inside human cells and is one of the most common sexually transmitted infections in people worldwide — about 2.8 million cases of chlamydia infection occur in the United States each year.[1] Chlamydia can be transmitted during vaginal, anal, or oral sex, and can be passed from an infected mother to her baby during vaginal childbirth. Many people with Chlamydia exhibit no symptoms of infection. Between half and three-quarters of all women who have chlamydia have no symptoms and do not know that they are infected. If untreated, chlamydial infections can cause serious reproductive and other health problems with both short-term and long-term consequences. Chlamydia is easily treated with antibiotics.
Of equal importance, chlamydia infection of the eye is the most common cause of preventable blindness in the world. Blindness occurs as a complication of trachoma (chlamydia conjunctivitis).[1]
Symptoms
PID can cause scarring inside the reproductive organs, which can later cause serious complications, including chronic pelvic pain, difficulty becoming pregnant, ectopic (tubal) pregnancy, and other dangerous complications of pregnancy. Chlamydia causes 250,000 to 500,000 cases of PID every year in the U.S. Women infected with chlamydia are up to five times more likely to become infected with HIV, if exposed.[1]
Chlamydia is known as the "Silent Epidemic" because in women, it may not cause any symptoms and will linger for months or years before being discovered. Symptoms that may occur include: unusual vaginal bleeding or discharge, pain in the abdomen, painful sexual intercourse (dyspareunia), fever, painful urination or the urge to urinate more frequently than usual.
Chlamydia may also cause reactive arthritis, especially in young men. About 15,000 men develop reactive arthritis due to chlamydia infection each year in the USA, and about 5,000 are permanently affected by it. The triad of reactive arthritis, conjunctivitis and urethritis (inflammation of the urethra) is known as Reiter's Syndrome. All three entities must be present for this label to be used. It can occur in both men and women, though is more common in men.
As many as half of all infants born to mothers with chlamydia will be born with the disease. Chlamydia can affect infants by causing spontaneous abortion; premature birth; conjunctivitis, which may lead to blindness; and pneumonia. Conjunctivitis due to chlamydia typically occurs one week after birth (Compare with chemical causes (within hours) or gonorrhea (2-5 days)).
Detection
The diagnosis of genital chlamydial infections evolved rapidly from the 1990s through 2006. Nucleic acid amplification tests (NAAT), such as polymerase chain reaction (PCR), transcription mediated amplification (TMA), and the DNA strand displacement assay (SDA) now are the mainstays. As of January 2007, the most commonly used and widely studied chlamydia NAATs in the US and many other industrialized countries are Aptima (Gen-Probe), Probe-Tec (Becton-Dickinson), and Amplicor (Roche). The Aptima Combo II assay tests simltaneously for C. trachomatis and Neisseria gonorrhoeae, the cause of gonorrhea. NAAT for chlamydia may be performed on swab specimens collected from the cervix (women) or urethra (men), on self-collected vaginal swabs, or on voided urine. Urine and self-collected swab testing facilitates the performance of screening tests in settings where genital examination is impractical. At present, the NAATs have regulatory approval only for testing urogenital specimens, although rapidly evolving research indicates that the Aptima test may give reliable results on rectal specimens.
Because of improved test accuracy, ease of specimen management, convenience in specimen management, and ease of screening sexually active men and women, the NAATs have largely replaced culture, the historic gold standard for chlamydia diagnosis, and the non-amplified probe tests, such as Pace II (Gen-Probe). The latter test is relatively insensitive, successfully detecting only 60-80% of infections in asymptomatic women, and often giving falsely positive results. Culture remains useful in selected circumstances and is currently the only assay approved for testing non-genital specimens.
Treatment
C. trachomatis infection can be effectively cured with antibiotics once it is detected. Current Centers for Disease Control guidelines provide for the following treatments:
- Azithromycin 1 gram oral as a single dose, or
- Doxycycline 100 milligrams twice daily for seven days.
- Tetracycline
- Erythromycin
Untested Treatments
- Ciprofloxacin 500 milligrams twice daily for 3 days. (Although this is not an approved method of treatment, as it is shown to be ineffective and may simply delay symptoms.)
β-lactams are not suitable drugs for the treatment of chlamydia. While they have the ability to halt growth of the organism (i.e. are microbistatic), these antibiotics do not eliminate the bacteria. Once treatment is stopped, the bacteria will begin to grow once more. (See below for Persistence.)
Pathophysiology
Chlamydial life cycle
Chlamydiae are obligate intracellular bacterial pathogens, which means they are unable to replicate outside of a host cell. However, to disseminate effectively, these pathogens have evolved a unique biphasic life cycle wherein they alternate between two functionally and morphologically distinct forms. [1]
- The elementary body (EB) is infectious, but metabolically inert (much like a spore), and can survive for limited amounts of time in the extracellular milieu. Once the EB attaches to a susceptible host cell, it mediates its own internalization through pathogen-specified mechanisms (via type III secretion system) that allows for the recruitment of actin with subsequent engulfment of the bacterium.
- The internalized EB, within a membrane-bound compartment, immediately begins differentiation into the reticulate body (RB). RBs are metabolically active but non-infectious, and in many regards, resemble normal replicating bacteria. The intracellular bacteria rapidly modifies its membrane-bound compartment into the so-called chlamydial inclusion so as to prevent phagosome-lysosome fusion. According to published data, the inclusion has no interactions with the endocytic pathway and apparently inserts itself into the exocytic pathway as it retains the ability to intercept sphingomyelin-containing vesicles.
To date, no one has been able to detect a host cell protein that is trafficked to the inclusion through the exocytic pathway. As the RBs replicate, the inclusion grows as well to accommodate the increasing numbers of organisms. Through unknown mechanisms, RBs begin a differentiation program back to the infectious EBs, which are released from the host cell to initiate a new round of infection. Because of their obligate intracellular nature, Chlamydiae have no tractable genetic system, unlike E. coli, which makes Chlamydiae and related organisms difficult to investigate.
Persistence
Chlamydiae have the ability to establish long-term associations with host cells. When an infected host cell is starved for various nutrients such as amino acids (e.g. tryptophan),[1] iron, or vitamins, this has a negative consequence for Chlamydiae since the organism is dependent on the host cell for these nutrients.
The starved chlamydiae enter a persistent growth state wherein they stop cell division and become morphologically aberrant by increasing in size.[1] Persistent organisms remain viable as they are capable of returning to a normal growth state once conditions in the host cell improve.
There is much debate as to whether persistence has in vivo relevance. Many believe that persistent chlamydiae are the cause of chronic chlamydial diseases. Some antibiotics such as β-lactams can also induce a persistent-like growth state, which can contribute to the chronicity of chlamydial diseases.
Diseases caused by Chlamydia trachomatis
Chlamydia trachomatis can cause the following conditions:
Recent genetic discoveries
Recent phylogenetic studies have revealed that chlamydia shares a common ancestor with modern plants, and retains unusual plant-like traits (both genetically and physiologically). In particular, the enzyme L,L-diaminopimelate aminotransferase, which is related to lysine production in plants, is also linked with the construction of chlamydia's cell wall. The genetic encoding for the enzymes is remarkably similar in plants and chlamydia, demonstrating a close common ancestry.[1]
This unexpected discovery may help scientists develop new treatment avenues: if scientists could find a safe and effective inhibitor of L,L-diaminopimelate aminotransferase, they might have a highly effective and extremely specific new antibiotic against chlamydia.
References
External links
- "Chlamydia: Questions and Answers" from Planned Parenthood
- NetDoctor Chlamydia fact sheet
- Links to chlamydia pictures at University of Iowa
- Chlamydiae.com - Information for patients, as well as for doctors and researchers about Chlamydial infections. Note: Patient info is in multiple languages.
ar:كلاميديا da:Klamydia de:Chlamydienfr:Chlamydiose it:Infezioni da clamidia he:כלמידיה mk:Хламидија ms:Penyakit kelamin Chlamydia nl:Chlamydia ja:クラミジア no:Klamydia-infeksjonsl:Klamidioza fi:Klamydia sv:Klamydia ta:கிளமிடியா
WikiDoc Research Resources for Chlamydia infection (Click show to right to view) | |
|---|---|
| Articles on Chlamydia infection | Most recent articles on Chlamydia infection • Most cited articles on Chlamydia infection • Review articles on Chlamydia infection • Articles on Chlamydia infection in N Eng J Med, Lancet, BMJ |
| Media (Slides, Video, Images, MP3) on Chlamydia infection | Powerpoint slides on Chlamydia infection • Images of Chlamydia infection • Photos of Chlamydia infection • Podcasts & MP3s on Chlamydia infection • Videos on Chlamydia infection |
| Evidence Based Medicine Regarding Chlamydia infection | Cochrane Collaboration on Chlamydia infection • Bandolier on Chlamydia infection • TRIP on Chlamydia infection |
| Cost Effectiveness of Chlamydia infection | Cost Effectiveness of Chlamydia infection |
| Clinical Trials Involving Chlamydia infection | Ongoing Trials on Chlamydia infection at Clinical Trials.gov • Trial results on Chlamydia infection • Clinical Trials on Chlamydia infection at Google |
| Guidelines / Policies / Government Resources (FDA/CDC) Regarding Chlamydia infection | US National Guidelines Clearinghouse on Chlamydia infection • NICE Guidance on Chlamydia infection • NHS PRODIGY Guidance • FDA on Chlamydia infection • CDC on Chlamydia infection |
| Textbook Information on Chlamydia infection | Books and Textbook Information on Chlamydia infection |
| Pharmacology Resources on Chlamydia infection | Dosing of Chlamydia infection • Drug interactions with Chlamydia infection • Side effects of Chlamydia infection • Allergic reactions to Chlamydia infection • Overdose information on Chlamydia infection • Carcinogenicity information on Chlamydia infection • Chlamydia infection in pregnancy • Pharmacokinetics of Chlamydia infection • |
| Genetics, Pharmacogenomics, and Proteinomics of Chlamydia infection | Genetics of Chlamydia infection • Pharmacogenomics of Chlamydia infection • Proteomics of Chlamydia infection |
| Newstories on Chlamydia infection | Chlamydia infection in the news • Be alerted to news on Chlamydia infection • News trends on Chlamydia infection |
| Commentary on Chlamydia infection | Blogs on Chlamydia infection |
| Patient Resources on Chlamydia infection | Patient resources on Chlamydia infection • Discussion groups on Chlamydia infection • Patient Handouts on Chlamydia infection • Directions to Hospitals Treating Chlamydia infection • Risk calculators and risk factors for Chlamydia infection |
| Healthcare Provider Resources on Chlamydia infection | Symptoms of Chlamydia infection • Causes & Risk Factors for Chlamydia infection • Diagnostic studies for Chlamydia infection • Treatment of Chlamydia infection |
| Continuing Medical Education (CME) Programs on Chlamydia infection | CME Programs on Chlamydia infection |
| International Resources on Chlamydia infection | Chlamydia infection en Espanol • Chlamydia infection en Francais |
| Business Resources on Chlamydia infection | Chlamydia infection in the Marketplace • Patents on Chlamydia infection |
| Informatics Resources on Chlamydia infection | List of terms related to Chlamydia infection |
| ||||
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
